

Learn how to improve your safety reporting process

The results teams like yours are experiencing with psiXchange 3.0

[Book demo](#)

If you're like most safety and clinical teams today, you face increasing pressure to improve efficiency and accuracy while reducing costs—often while working with limited resources and navigating a complex regulatory landscape.

We'd like to show you an easier way to manage your safety reporting process through our automated software solution, psiXchange 3.0.

What does psiXchange deliver?

- Up to 90% reduction in time per submission*
- Up to 80% reduction in operational costs*
- Up to 95% site responsiveness rates**
- Up to 90% reduction in resourced demand*

Let's schedule a time for us to show you an easier, improved way to handle safety reporting with a no-pressure **product demo**.

[Book a Demo](#)

*Customer-related outcomes; actual results may vary.

** System data for multinational biopharmaceutical company – site responsiveness improved from 41.2% to 75.2% within 12 months and to 95.2% within 24 months.

Insider Expertise on the Clinical Trial Regulation

Discover Insider Expertise on CTR

[Read blog](#)

Elise,

Is your organization struggling with the substantial modification under the Clinical Trials Regulation (CTR)? The rules around when, how, and if sponsors need to update a transitioned dossier can be challenging to decipher.

Our team is here to help with a [blog post](#) that covers:

- **Timing Considerations.** Submitting a substantial modification immediately after transition may not always be necessary. We provide insights into the optimal timing strategies to ensure compliance without unnecessary complications.
- **Guided Compliance.** Managing substantial modifications requires a comprehensive understanding of official guidance. Our expert analysis simplifies this process, allowing you to navigate the complexity confidently.
- **Insider Expertise:** Discover practical strategies and recommendations from industry experts for effectively addressing substantial modifications while maintaining compliance with the CTR.

[Contact us](#) if you would like to speak with a Clinical Trial Regulation specialist.

[Discover Insider Expertise on CTR](#)